HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by research analysts at HC Wainwright in a report released on Monday,Benzinga reports.

A number of other equities research analysts also recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Evercore ISI downgraded shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price objective for the company. in a research report on Thursday, May 8th. Leerink Partnrs cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. Wells Fargo & Company upped their price target on shares of Sarepta Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Finally, Mizuho reiterated a “neutral” rating and issued a $14.00 target price (down from $40.00) on shares of Sarepta Therapeutics in a research note on Monday, July 21st. Eight research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and an average price target of $43.50.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.54 during mid-day trading on Monday, hitting $18.61. 2,838,522 shares of the company were exchanged, compared to its average volume of 6,258,188. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $140.10. The business has a 50 day simple moving average of $17.81 and a 200-day simple moving average of $48.74. The stock has a market capitalization of $1.82 billion, a PE ratio of -21.40 and a beta of 0.46. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. During the same period last year, the firm posted $0.07 earnings per share. The firm’s quarterly revenue was up 68.4% compared to the same quarter last year. On average, equities analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in SRPT. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics in the first quarter worth approximately $31,000. Logan Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $61,000. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. Finally, Pandora Wealth Inc. purchased a new stake in Sarepta Therapeutics during the first quarter valued at approximately $45,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.